CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)

Summary

This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line treatment (EOT), as defined by positive measurable residual disease detected by Foresight CLARITY (PhasED-seq). Participants will initially be pre-screened for MRD status after first line treatment (1L) with chemoimmunotherapy including a CD20 monoclonal antibody and anthracycline.

Timeline

Start

2026-07

Primary completion

2028-08

Completion

2028-08

Drugs

Indications